Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03276676 · ClinicalTrials.gov registry record · Phase 1
[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors
A Phase 1 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03276676 is a Phase 1 study that was terminated before completion, run by University of Utah. The registered enrollment target is 10 participants.
The verdict
NCT03276676, a Phase 1 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The hypothesis of this exploratory clinical trial in patients with high-grade a primary brain tumor who receive chemoradiation is that the PET imaging agents \[18F\]Fluciclovine and/or \[18F\]FLT will be a better predictor of tumor response than standard MRI based brain tumor response criteria. When used in conjunction, the two PET agents may be better able to predict tumor aggressiveness and thus overall survival than the use of individual-tracer PET biomarkers. This may eventually lead to improved assessment of response (including time to progression and overall survival) and differentiation of tumor recurrence/progression from treatment effect (pseudoprogression).
Interventions
- DRUG [18F]FLT
- DRUG [18F]Fluciclovine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-09-24 |
| Est. Completion | 2023-08-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03276676
The ClinicalTrials.gov registry entry for NCT03276676 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which [18F]FLT is the first listed.
NCT03276676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03276676 about?
NCT03276676 is a clinical study titled "[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors". The hypothesis of this exploratory clinical trial in patients with high-grade a primary brain tumor who receive chemoradiation is that the PET imaging agents \[18F\]Fluciclovine and/or \[18F\]FLT will be a better predictor of tumor response than standard MRI based brain tumor response criteria. When...
What is the current status of trial NCT03276676?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2018-09-24. Estimated completion is 2023-08-18.
What interventions are being tested in trial NCT03276676?
The interventions under investigation include: [18F]FLT (DRUG), [18F]Fluciclovine (DRUG).
Who is sponsoring clinical trial NCT03276676?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.